Faruqi & Faruqi, LLP reminds investors of the August 3, 2026 deadline to seek lead plaintiff in a securities class action against GeneDx Holdings Corp. The lawsuit alleges the company made false and misleading statements about its Fabric Genomics acquisition, the durability of average reimbursement rates, and gross margins. On May 4, 2026, GeneDx disclosed first-quarter results missed expectations, cut 2026 revenue guidance from $540-555 million to $475-490 million, reported average reimbursement rates of $3,300, and took a $31.3 million goodwill impairment charge on the Fabric Genomics acquisition it had purchased for $36.5 million a year earlier. The company's share price fell over 49%, or $33.42 per share, on the news. Investors who purchased GeneDx securities between April 16, 2025 and May 4, 2026 may contact the firm to discuss their legal rights.
GeneDx Holdings Corp.Securities class action lawsuit alleging false statements, missed Q1 expectations, revenue guidance cut, and goodwill impairment charge caused 49% stock drop.